Karessa has signed an agreement with PCG Clinical Services AB for performance of a clinical study within the project K-03
Karessa Pharma Holding AB announces today that an agreement between Karessa and PCG Clinical Services AB has been signed for the performance of a first human study within the project K-03.The study, which is the first one with Vardenafil formulated in Karessa's unique buccal film for delivery via the mucous membrane in the mouth, aim to evaluate different doses and formulations in a pharmacokinetic study on healthy human. The goal is to show which dose and formulation that are most suitable to use in a pivotal study. The start of the agreed study is scheduled to take place in the fourth